上海医药1类创新药信妥安正式获批上市

Core Insights - Shanghai Pharmaceuticals has received approval for its innovative drug, Suojirolin tablets, aimed at treating primary hypertension, marking a significant achievement in its commitment to innovation in the pharmaceutical sector [2] Group 1: Drug Development and Approval - The innovative drug Suojirolin has been in clinical research since 2016 and is expected to be commercially available by 2025, addressing unmet clinical needs for over 300 million patients with primary hypertension in China [2] - The Phase II clinical trial results for Suojirolin have been published in the authoritative cardiovascular journal "Hypertension Research," with ongoing efforts to publish Phase III study results, highlighting the global academic interest in Chinese innovative drugs [2] Group 2: Research and Development Investment - Shanghai Pharmaceuticals plans to invest a total of 2.818 billion yuan in research and development in 2024, emphasizing its strategic focus on innovation [2] - As of the end of Q3 2025, the company has submitted 57 new drug applications for clinical trials, with 45 of these being innovative drug pipelines, establishing a comprehensive and tiered R&D structure [2] Group 3: Collaborative Innovation Ecosystem - The company has established the "Shanghai Frontier" life sciences innovation incubation engine in collaboration with universities and top research institutions, attracting numerous renowned research and service organizations since its launch in September of last year [3][4] - Shanghai Pharmaceuticals aims to continue investing in innovative R&D, focusing on urgent clinical needs in areas such as oncology, immunology, cardiovascular health, mental health, digestive metabolism, and anti-infection, while enhancing the collaborative innovation ecosystem [4]